

Stefano Ballestri

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3077412/stefano-ballestri-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

3,898
citations

28
h-index

53
g-index

53
ext. papers

4,800
ext. citations

5.1
avg. IF

5.52
L-index

#	Paper	IF	Citations
52	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. <i>Digestive and Liver Disease</i> , 2015 , 47, 181-90	3.3	430
51	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 936-44	4	378
50	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 830-40	4	364
49	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. <i>Digestive and Liver Disease</i> , 2015 , 47, 997-1006	3.3	279
48	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. <i>Hepatology</i> , 2019 , 70, 1457-1469	11.2	238
47	NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. <i>Advances in Therapy</i> , 2017 , 34, 1291-1326	4.1	232
46	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1724-45	5.6	160
45	Nonalcoholic fatty liver disease and aging: epidemiology to management. <i>World Journal of Gastroenterology</i> , 2014 , 20, 14185-204	5.6	158
44	Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. <i>Gut</i> , 2016 , 65, 861-9	19.2	136
43	Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. <i>Liver International</i> , 2012 , 32, 1242-52	7.9	124
42	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014 , 232, 99-109	3.1	97
41	The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. <i>Hepatology Research</i> , 2016 , 46, 1074-1087	5.1	82
40	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	81
39	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. <i>Metabolism: Clinical and Experimental</i> , 2017 , 72, 57-65	12.7	80
38	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 603-27	4.2	79
37	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1246-67	4	75
36	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9674-9693	5.6	69

35	Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7089-103	5.6	66
34	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 629-50	4.2	57
33	Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?. <i>Internal and Emergency Medicine</i> , 2013 , 8, 297-305	3.7	57
32	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. <i>Advances in Therapy</i> , 2016 , 33, 291-319	4.1	54
31	Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011 , 5, 253-63	4.2	48
30	Fatty liver, carotid disease and gallstones: a study of age-related associations. <i>World Journal of Gastroenterology</i> , 2006 , 12, 5826-33	5.6	46
29	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
28	A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?. <i>Acta Diabetologica</i> , 2019 , 56, 385-396	3.9	42
27	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 351-367	4.2	34
26	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 355	6.3	30
25	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. <i>Archives of Medical Research</i> , 2011 , 42, 337-53	6.6	29
24	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. <i>Digestive and Liver Disease</i> , 2019 , 51, 462-470	3.3	26
23	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 1458-1468	5.6	26
22	Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. <i>Advances in Therapy</i> , 2020 , 37, 1910-1932	4.1	25
21	Hepatitis C virus-infected patients are compared from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009 , 23, 273-8		24
20	A critical appraisal of the use of ultrasound in hepatic steatosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 667-681	4.2	23
19	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. <i>Diagnostics</i> , 2021 , 11,	3.8	22
18	Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. <i>Metabolic Syndrome and Related Disorders</i> , 2013 , 11, 289-95	2.6	21

17	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. <i>Future Medicinal Chemistry</i> , 2019 , 11, 2171-2192	4.1	18
16	Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. <i>Archives of Medical Research</i> , 2011 , 42, 690-7	6.6	16
15	Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?. <i>Digestive and Liver Disease</i> , 2014 , 46, 288-9	3.3	15
14	Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?. <i>Diseases (Basel, Switzerland)</i> , 2018 , 6,	4.4	13
13	Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. <i>Gastroenterology</i> , 2011 , 140, 1694-5	13.3	13
12	Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. <i>Antiviral Therapy</i> , 2012 , 17, 965-71	1.6	10
11	Perspectives of nonalcoholic fatty liver disease research: a personal point of view 2020 , 1, 85-107		10
10	Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. <i>Internal and Emergency Medicine</i> , 2009 , 4, 71-3	3.7	8
9	Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?. <i>Hepatology</i> , 2011 , 53, 2142-3; author reply 2143	11.2	7
8	Semi-Quantitative Ultrasonographic Evaluation of NAFLD. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3915-3927	3.3	7
7	Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. <i>Journal of Clinical Virology</i> , 2015 , 69, 74-7	14.5	6
6	Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings. <i>Journal of Medical Ultrasonics (2001)</i> , 2015 , 42, 251-5	1.4	5
5	The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. <i>Hepatology</i> , 2008 , 47, 361-2	11.2	5
4	Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 278; author reply 278-81	3.1	4
3	Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. <i>Hepatology Research</i> , 2012 , 42, 945	5.1	3
2	NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk. <i>Hepatology</i> , 2017 , 65, 2122-2123	11.2	2
1	Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. <i>Liver International</i> , 2015 , 35, 2340-1	7.9	1